What Cardiovascular Systems does

Cardiovascular Systems Inc. (CSI) was a Minnesota-incorporated medical device company founded in 1989 and headquartered at 1225 Old Highway 8 NW, St. Paul, Minnesota. The company developed and commercialized catheter-based orbital atherectomy systems (OAS) used by interventional cardiologists and vascular surgeons to treat complex peripheral and coronary artery disease. Its core technology uses a diamond-coated crown that orbits at high speed to sand away calcified arterial plaque while preserving healthy vessel tissue, and the franchise comprised the Diamondback 360 (peripheral and coronary) and Stealth 360 peripheral systems in multiple generations and crown configurations (Gen 2, Classic Crown, Micro Crown, Solid Crown with Prime Button, and Exchangeable Series).

CSI monetized primarily through direct enterprise sales of OAS capital equipment, single-use catheters, and a recurring consumables ecosystem — including ViperWire Advance peripheral guide wires, ViperCross support catheters, Shepherd guidewires, ViperCath exchange catheters, ViperSlide lubricant, and a saline infusion pump — sold to acute care hospitals with interventional cardiology/vascular surgery departments and to outpatient vascular treatment centers. Pricing was conducted through negotiated enterprise contracts with healthcare providers rather than disclosed list pricing.

In April 2023, Abbott Laboratories acquired CSI for approximately $890 million, delisting the company from NASDAQ (ticker: CSII) and integrating the orbital atherectomy franchise into Abbott's Medical Devices vascular portfolio, complementing Abbott's existing peripheral thrombectomy systems acquired via Walk Vascular in 2021. Post-acquisition, CSI operates as a wholly-owned subsidiary of Abbott, the CSI360 website now redirects messaging to Abbott, and the firm no longer publishes standalone financial results. The company employs 501–1,000 people and is exposed to ongoing federal whistleblower litigation alleging Anti-Kickback Statute violations tied to a Hawai'i outpatient vascular center.

Name

Cardiovascular Systems

Legal name

Cardiovascular Systems, Inc.

Website

https://csi360.com

Company type

Private

Founded year

1989

Operating status

Acquired

Headcount range

501–1,000 employees

Short description

Cardiovascular Systems developed catheter-based orbital atherectomy systems (Diamondback 360, Stealth 360) to treat complex peripheral and coronary artery disease, selling directly to hospitals and outpatient vascular centers. Acquired by Abbott Laboratories in April 2023 for approximately $890 million.

Ownership category

akta.pro rank

Product category

Vascular Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems) (HLAHAFAK)

Keywords

• Orbital atherectomy systems
• Peripheral artery disease
• Coronary atherectomy devices
• Catheter-based medical devices
• Vascular intervention products

Headquarters

HQ city

Saint Paul

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Medical Device Sales: Cardiovascular Systems generated revenue through the sale of orbital atherectomy systems, guide wires, support catheters, and related accessories to hospitals and outpatient vascular treatment centers. Following Abbott's acquisition in April 2023, CSI's products became part of Abbott's Medical Devices portfolio.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Cardiovascular Systems develops and sells catheter-based orbital atherectomy systems, including the Diamondback 360 and Stealth 360 systems, for the minimally invasive treatment of calcified plaque in peripheral and coronary arteries. The product line is supported by a comprehensive ecosystem of accessory devices including ViperWire Advance guide wires, ViperCross support catheters, Shepherd guidewires, exchange catheters, lubricants, and saline infusion pumps sold to hospitals and outpatient vascular treatment centers.

Product overview

Cardiovascular Systems Inc. (CSI), now part of Abbott's Medical Devices portfolio, is a medical devices company specializing in catheter-based orbital atherectomy systems for treating complex peripheral and coronary artery diseases. The core product line centers on the Diamondback 360 and Stealth 360 Orbital Atherectomy Systems, which use a diamond-coated crown that orbits at high speed to sand away calcified plaque while preserving healthy vessel tissue. The product portfolio spans both peripheral and coronary applications, with the Diamondback 360 available in multiple crown sizes (Classic, Micro, Solid) and generations (Gen 1, Gen 2). Supporting the primary OAS systems is a comprehensive ecosystem of accessories including ViperWire Advance guidewires, ViperCross support catheters, Shepherd guidewires, ViperCath exchange catheters, ViperSlide lubricant, and saline infusion pumps. Abbott expanded its vascular offerings by acquiring CSI in 2023, adding these atherectomy technologies to its existing peripheral thrombectomy capabilities acquired through Walk Vascular in 2021.

Differentiator

Problem solved

Functional benefit

Brands

• Diamondback 360: Peripheral and Coronary Orbital Atherectomy System used to treat plaque buildup in arteries
• Stealth 360
• ViperWire Advance
• ViperCross
• Shepherd

Products and services

• Diamondback 360 Peripheral Orbital Atherectomy System (OAS) Catheter-based orbital atherectomy system used to treat plaque buildup in peripheral arteries by sanding away calcium with a diamond-coated orbiting crown while preserving healthy vessel tissue. Available in Gen 2, Classic Crown, and Micro Crown variants and sold to hospitals with interventional cardiology and vascular surgery departments.
• Stealth 360 Peripheral Orbital Atherectomy System (OAS) Peripheral orbital atherectomy system for treating plaque buildup in peripheral arteries, including complex lesions. Available in Gen 2 and Solid Crown variants with Prime Button configuration and sold to interventional vascular healthcare providers.
• Diamondback 360 Coronary Orbital Atherectomy System Coronary-specific orbital atherectomy system designed for treating calcified coronary arteries. Available in Precision, Classic Crown with GlideAssist, and Micro Crown configurations and sold to interventional cardiology departments.
• ViperWire Advance Peripheral Guide Wire Specialized guide wire used to navigate peripheral vasculature during orbital atherectomy procedures, providing support and trackability for catheter advancement through complex lesions. Sold to hospitals and outpatient vascular centers.
• ViperCross Support Catheter Support catheter available in 014 and 018/035 sizes designed to provide enhanced trackability and support during peripheral interventions, facilitating crossing of complex lesions during atherectomy procedures. Sold as a standalone accessory to healthcare providers.
• Shepherd Peripheral Guidewire Peripheral guidewire designed for navigating complex vasculature during atherectomy procedures. Sold as a standalone accessory device to vascular interventionalists.
• ViperSlide Lubricant Lubricant solution used during orbital atherectomy procedures to facilitate device navigation and reduce friction. Sold as a standalone accessory to healthcare providers performing atherectomy.
• ViperCath XC Peripheral Exchange Catheter Exchange catheter designed for peripheral interventions, enabling device exchange during atherectomy procedures. Sold as a standalone accessory to vascular interventionalists.
• Peripheral OAS Saline Infusion Pump Saline infusion pump system that delivers irrigation during orbital atherectomy procedures, used with both peripheral and coronary OAS systems. Sold as a standalone accessory to healthcare providers performing atherectomy.

Quantifiable outcome

• Atherectomy devices market growing at 6.7% CAGR from USD 1,054.6 million in 2024 to USD 1,945.0 million by 2033

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Abbott LaboratoriescoreStrategic or Co-development Partner · 1 April 2023Abbott Laboratories acquired Cardiovascular Systems Inc. in April 2023 for approximately $890 million to strengthen its vascular portfolio with CSI's orbital atherectomy systems for treating complex peripheral and coronary artery diseases. CSI became a subsidiary of Abbott, with its products integrated into Abbott's Medical Devices portfolio. CSI's Diamondback 360 and Stealth 360 systems complement Abbott's existing vascular offerings including peripheral thrombectomy systems acquired through Walk Vascular in 2021.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Medtronic: Medtronic is a broad incumbent in interventional cardiology and peripheral vascular devices, with drug-coated balloons, stents, and atherectomy-related products that compete with the Abbott/CSI vascular portfolio across coronary and peripheral indications.
• BD (Becton Dickinson): BD operates in peripheral vascular intervention through its acquisition of Venclose and its broader peripheral access portfolio, competing in adjacent device categories and hospital vascular accounts where CSI sells its atherectomy systems.
• Philips (Igt Medical / Volcano): Philips offers directional atherectomy and broader image-guided therapy systems in the peripheral and coronary intervention space, making it an incumbent competitor to the Abbott/CSI atherectomy franchise.
• Abbott Laboratories (Parent Vascular Franchise): Abbott's broader vascular franchise (including XIENCE stents, peripheral product lines, and Walk Vascular thrombectomy) is the parent context in which CSI now operates and competes with internal portfolio prioritization alongside its own atherectomy systems.

Direct peers

• Boston Scientific: Boston Scientific competes directly in the atherectomy and vascular intervention space with its Rotablator rotational atherectomy system, and operates a broad interventional cardiology and peripheral vascular portfolio comparable to Abbott's vascular franchise that now houses CSI.
• Shockwave Medical (Johnson & Johnson): Shockwave Medical's intravascular lithotripsy (IVL) is a competing calcium-modification modality for both coronary and peripheral applications, directly addressing the same calcified lesion challenge that CSI's orbital atherectomy targets.
• AngioDynamics: AngioDynamics offers the Auryon atherectomy system for peripheral artery disease, directly competing with CSI's peripheral orbital atherectomy products in the same hospital and outpatient vascular accounts.
• Penumbra: Penumbra's peripheral thrombectomy systems (Indigo and Lightning systems) compete for the same hospital vascular accounts and increasingly overlap with CSI's peripheral procedures, particularly in the outpatient vascular treatment setting.

Emerging players

• Avinger: Avinger develops image-guided catheter-based systems for the treatment of peripheral artery disease, including the Pantheris directional atherectomy system, representing an emerging niche competitor to CSI's orbital atherectomy platform.
• Ra Medical Systems: Ra Medical Systems developed laser atherectomy catheters for peripheral and coronary applications, offering a competing technology approach to calcified plaque removal, though it has faced commercial and financial challenges.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/csi360

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds12 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cardiovascular Systems